GLP-1 Cardiovascular Benefit Calculator

The GLP-1 Cardiovascular Benefit Calculator estimates the reduction in major adverse cardiovascular events (MACE) risk for patients taking GLP-1 receptor agonist medications. The landmark SELECT trial, published in 2023, demonstrated that semaglutide 2.4 mg reduced the composite MACE endpoint (cardiovascular death, non-fatal heart attack, and non-fatal stroke) by 20 percent in patients with overweight or obesity and established cardiovascular disease but without diabetes. This was the first trial to prove that a weight loss medication could prevent heart attacks and strokes. The cardiovascular benefits of GLP-1 medications extend beyond their weight loss effects. Research suggests these drugs reduce atherosclerotic inflammation, improve endothelial function, lower blood pressure by 4 to 6 mmHg, reduce LDL cholesterol and triglycerides, and decrease C-reactive protein (a marker of systemic inflammation). These pleiotropic effects mean that the cardiovascular risk reduction exceeds what would be expected from weight loss alone, positioning GLP-1 medications as a new class of cardiovascular prevention therapy. Prior to SELECT, the LEADER trial had shown a 13 percent MACE reduction with liraglutide 1.8 mg in patients with type 2 diabetes, and the SUSTAIN-6 trial showed a 26 percent reduction with semaglutide 1.0 mg in diabetes patients. The SELECT trial was groundbreaking because it enrolled patients without diabetes, demonstrating cardiovascular benefit from GLP-1 therapy independent of glycemic effects. This finding transformed semaglutide from a diabetes/obesity medication into a cardiovascular prevention drug. The calculator is used by cardiologists evaluating whether to add GLP-1 therapy to their cardiovascular prevention toolkit, by internists managing patients with obesity and cardiovascular risk, by insurance companies assessing the value proposition of covering expensive GLP-1 medications on the basis of cardiovascular event prevention, and by health economists modeling the cost-effectiveness of GLP-1 therapy when downstream cardiovascular event savings are included.

1. 1Enter your cardiovascular risk profile including age, sex, smoking status, blood pressure, total and HDL cholesterol, and diabetes status. The calculator computes your baseline 10-year ASCVD (atherosclerotic cardiovascular disease) risk using the Pooled Cohort Equations endorsed by the ACC/AHA. This baseline risk is the foundation for estimating the absolute benefit of GLP-1 therapy, because patients with higher baseline risk derive greater absolute benefit from the same relative risk reduction.
2. 2Indicate whether you have established cardiovascular disease (prior heart attack, stroke, coronary artery bypass, stenting, or peripheral artery disease) or are in the primary prevention category (risk factors but no events yet). The SELECT trial enrolled patients with established CVD and demonstrated the 20 percent MACE reduction in this secondary prevention population. The magnitude of benefit in primary prevention patients is extrapolated but likely smaller, and the calculator applies a conservative adjustment for patients without established CVD.
3. 3Select the GLP-1 medication you are taking or considering. The calculator uses the hazard ratio from the relevant cardiovascular outcomes trial (CVOT) for each medication. Not all GLP-1 medications have demonstrated cardiovascular benefit: semaglutide (SELECT, SUSTAIN-6) and liraglutide (LEADER) have positive CVOT results, while other GLP-1 medications have shown cardiovascular safety but not superiority over placebo. The calculator clearly distinguishes between proven benefit and assumed benefit based on class effect.
4. 4The calculator computes your baseline 5-year and 10-year MACE risk, the estimated risk with GLP-1 therapy, the absolute risk reduction, and the number needed to treat (NNT). Higher-risk patients see lower NNTs, meaning the treatment is more efficient per patient treated. For a patient with 20 percent 5-year MACE risk, the NNT with semaglutide is approximately 25, while for a patient with 5 percent risk, the NNT rises to approximately 100.
5. 5Review the breakdown of cardiovascular benefit components: MACE composite risk reduction, individual estimates for cardiovascular death, non-fatal MI, and non-fatal stroke, as well as secondary outcomes including heart failure hospitalization, all-cause mortality, and kidney outcomes. The SELECT trial showed reductions across most individual components, though the primary endpoint was the MACE composite.
6. 6The economic impact module estimates the monetary value of cardiovascular event prevention. The average cost of a heart attack in the US is approximately $50,000 to $100,000 for the acute hospitalization alone, with ongoing management costs of $10,000 to $20,000 per year. A stroke costs $30,000 to $80,000 for acute care with significant ongoing rehabilitation and disability costs. These potential savings are weighed against the annual cost of GLP-1 therapy to determine the cardiovascular cost-effectiveness ratio.
7. 7Generate a risk-benefit summary showing cardiovascular benefit alongside potential side effects and medication cost to support shared decision-making with your physician. The summary is designed as a one-page patient-facing document that presents the clinical evidence in plain language and can be used during office visits to discuss whether adding GLP-1 therapy for cardiovascular prevention is appropriate for your individual risk profile.